Sol serves as Vice President and Head of Chemistry and CMC at Terremoto.

Since 2013, Sol has served in roles bridging medicinal chemistry and R&D strategy in both small biotech and large pharma environments, including previous roles of increasing responsibility at Gilead Sciences, Schrodinger, and Third Rock Ventures. While at Third Rock he was part of the team that incubated Terremoto as a company concept before its eventual launch in 2021.

Sol earned a Ph.D. in Chemistry from Scripps Research, advised by Phil Baran, and a B.A. in Chemistry from Kenyon College.